肝癌患者微创治疗后复发较常见，过继免疫治疗被认为是一种降低肿瘤复发及转移的有效治疗手段.本研究纳入85例经TACE或RFA治疗患者，随机分入免疫治疗组与对照组。治疗组经肝动脉回输细胞因子诱导的自体杀伤细胞。通过流式细胞术分析患者外周血淋巴细胞亚群变化，每2个月复查CT，评价肿瘤复发情况.细胞回输后，治疗组患者外周血CD3+, CD4+, CD56+, CD3+CD56+ 细胞百分比及CD4+/CD8+ 比值分别由 68.6 ± 11.0%, 31.1 ± 9.0%, 15.6 ± 7.9%, 5.2 ± 3.1%, 1.1 ± 0.5 升高到 70.7 ±10 %, 33.5 ± 8.0%, 18.4 ± 9.4%, 5.9 ± 2.8%, 与1.3 ± 0.7 (P < 0.05)；而 CD8+ 细胞百分比由 31.1 ± 7.8% 降低到28.6 ± 8.3% (P <0.05)；治疗后1年及1年半复发率为8.9% 与15.6%, 明显低于对照组的 30.0%与40.0% (均P < 0.05). 结果提示，CIK细胞回输可能是一种有效治疗手段，可以增强HCC患者免疫力，降低复发.


Backgrounds and aims The recurrence of hepatocellular carcinoma (HCC) after minimally invasive therapy is frequent. Adoptive immunotherapy is thought to be an effective method to lower recurrence and metastasis rates of malignant tumors. Patients and Methods 85 HCC patients after transcatheter arterial chemoembolization and radiofrequency ablation therapy were randomized to immunotherapy group and no adjuvant therapy group. Autologous cytokine-induced killer (CIK) cells were transfused via hepatic artery to the patients. The alteration of levels of lymphocyte subsets in peripheral blood of patients was examined by flow cytometry. All patients were screened by computed tomography every 2 months to observe the tumor recurrent conditions. Results After CIK cell infusions, the percentages of CD3+, CD4+, CD56+, CD3+CD56+ cells, and CD4+/CD8+ ratio increased from 68.6 ± 11.0%, 31.1 ± 9.0%, 15.6 ± 7.9%, 5.2 ± 3.1%, and 1.1 ± 0.5 to 70.7 ±10 %, 33.5 ± 8.0%, 18.4 ± 9.4%, 5.9 ± 2.8%, and 1.3 ± 0.7, respectively (P < 0.05); whereas the percentage of CD8+ cells decreased from 31.1 ± 7.8% to 28.6 ± 8.3% (P <0.05). The 1-year and 18-month recurrence rates of the study group were 8.9% and 15.6%, compared with 30.0% and 40.0% of the control group (both P value < 0.05). Conclusion The data suggest that CIK cell transfusion is an effective treatment. It can boost the immunologic function in HCC patients and plays an important role in reducing the recurrence rate of HCC